US20100151445A1 - Multiplex Method for Detecting an Infection - Google Patents

Multiplex Method for Detecting an Infection Download PDF

Info

Publication number
US20100151445A1
US20100151445A1 US12/600,297 US60029708A US2010151445A1 US 20100151445 A1 US20100151445 A1 US 20100151445A1 US 60029708 A US60029708 A US 60029708A US 2010151445 A1 US2010151445 A1 US 2010151445A1
Authority
US
United States
Prior art keywords
microorganism
particles
hav
igm
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/600,297
Other languages
English (en)
Inventor
Christine Charpentier
Stephane Gadelle
Nadine Lambert
Amparo Sanjuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Rad Europe GmbH
Bio Rad Innovations SAS
Original Assignee
Bio Rad Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Rad Pasteur SA filed Critical Bio Rad Pasteur SA
Priority to US12/600,297 priority Critical patent/US20100151445A1/en
Publication of US20100151445A1 publication Critical patent/US20100151445A1/en
Assigned to BIO-RAD PASTEUR reassignment BIO-RAD PASTEUR ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHARPENTIER, CHRISTINE, GADELLE, STEPHANE, LAMBERT, NADINE, SANJUAN, AMPARO
Assigned to BIO-RAD INNOVATIONS reassignment BIO-RAD INNOVATIONS CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BIO-RAD PASTEUR
Assigned to BIO-RAD EUROPE GMBH reassignment BIO-RAD EUROPE GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIO-RAD INNOVATIONS
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • G01N2333/10—Hepatitis A virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the in vitro detection of an infection with an infectious, in particular viral, microorganism.
  • the invention relates to a method for simultaneously detecting total immunoglobulins and immunoglobulins M directed against this same infectious microorganism.
  • the invention relates more particularly to the simultaneous detection of total immunoglobulins and immunoglobulins M directed against a human hepatitis virus.
  • Infections caused by microorganisms in particular by viruses such as, for example, the hepatitis virus in humans, constitute in general a preoccupying health problem that has been recognized for a long time, in particular in blood transfusion and in diagnosis.
  • Immunoglobulins M which appear early and transiently, are the hallmark of a recent acute, or primary infection.
  • Total immunoglobulins which group together the various immunoglobulin isotypes (IgM, IgG and IgA) are the hallmark of the chronicity or duration of the infection over time, or else the convalescence phase of the patient.
  • IgM, IgG and IgA immunoglobulins M
  • IgM, IgG and IgA immunoglobulin isotypes
  • a considerable time after an acute infection the total immunoglobulins consist predominantly of IgG for supporting long-term immunity (Hollinger et al., Fields Virology, p. 735-785, 1996). For this reason, it is important to be able to differentiate, throughout an infection, between the IgMs and the total immunoglobulins in a patient. This is a very general situation in in vitro serology.
  • HAV hepatitis A virus
  • HBV hepatitis B virus
  • HSV herpes simplex virus
  • CMV Cytomegalovirus
  • dengue virus other flaviviruses (such as the West Nile Virus)
  • rubella virus the influenza virus
  • VZV Viaricella Zoster Virus
  • various bacteria Treponema pallidum, Borrelia burgdorferi , etc.
  • various single-cell parasites Toxoplasma gondii , for example).
  • FX Heinz, et al. “Comparison of two different enzyme immunoassays for detection of tick-borne encephalitis virus in serum and cerebrospinal fluid” ( Journal of Clinical Microbiology, 14: p. 141-146, (1981)), noted the existence, in an indirect EIA assay (immunoenzymatic assay) for detecting IgM, of competition between IgMs and IgGs, which affects the sensitivity and the specificity of the final detection.
  • EIA assay immunoenzymatic assay
  • any antigen bound to the well is then detected by means of a final incubation carried out in the presence of an antibody (F(ab′) 2 ) directed against the HAV antigen and labelled with an enzyme.
  • F(ab′) 2 an antibody directed against the HAV antigen and labelled with an enzyme.
  • U.S. Pat. No. 4,273,756 in the same way describes class-specific “immunoglobulin capture” formats for detecting IgAs, IgDs, IgEs, IgGs and IgMs directed against various hepatitis viruses (HAV, HBV).
  • Angarano et al. proposes a system for the simultaneous detection of anti-HBc IgMs and total Igs (essentially IgG), called RIELISA (Radio-Immune Enzyme-Linked-ImmunoSorbent Assay), which combines a competitive radioimmunoassay for detecting the total anti-HBc immunoglobulins (CORAB assay from Abbott Laboratories) with an indirect ELISA immunoassay for detecting the anti-HBc IgMs.
  • RIELISA Radio-Immune Enzyme-Linked-ImmunoSorbent Assay
  • the same antigen (recombined HBc antigen) is adsorbed onto a one and only solid phase (polystyrene bead, placed in a well), but, on the one hand, an antibody directed against the HBc antigen and radioactively labelled (iodine 125 ) is used for detecting the total anti-HBc immunoglobulins, and, on the other hand, an enzymatically labelled (with peroxydase) anti-IgM antibody is used for detecting the anti-HBc IgMs.
  • Angarano et al. specifies that the only essential point is that the labelling of the antigen-specific antibody should be different and should not interfere with that of the immunoglobulin-class-specific antibody.
  • the detection of IgMs and IgGs directed against the same virus is mainly carried out by performing two immunoassays on separate side phases, so as to avoid any possible interference between the two assays and to obtain clearly differentiated IgM and IgG signals.
  • Flow cytometry is based on the passage of a suspension of microparticles, in the form of a stream, in front of a light ray. Electro-optical sensors make sure that a single particle at a time passes in front of the light ray. The signal caused by the disturbance of the light ray as the particle passes is then detected and recorded.
  • U.S. Pat. No. 6,872,578 B2 describes in particular a multiplex immunoassay system (i.e. an immunoassay system with simultaneous detection of several analytes in a single sample).
  • This system combines, in a heterogeneous immunoassay, the use of flow cytometry and of several groups of solid particles. These particles are magnetic and each carries a specific detectable parameter (i.e. a physical characteristic such as, for example, a size, a unique colour or else a specific fluorescence).
  • Each group of microparticles comprises a range of values for differentiating the particles into several non-overlapping groups distinguishable by automated detection methods suitable for the parameters in question.
  • These particles each carry, bound to the surface, a different assay reagent from one group to the other. All the particles of the same group carry the same reagent.
  • the magnetic characteristic of these particles allows the separations of the solid and liquid phases to be automated during the washing.
  • U.S. Pat. No. 6,872,578 B2 describes, inter alia, an example of simultaneous detection of antibodies of various immunoglobulin classes (IgG and IgM) directed against the rubella virus antigen.
  • the IgGs and IgMs are immunopurified using a first magnetic particle sensitized with the antigen specific for the IgGs and IgMs to be detected. After this first incubation, the nonspecific immunoglobulins are eliminated during the washing. The specific immunoglobulins, which are captured by the antigen adsorbed onto the particle, are then released into the supernatant by adding acetic acid.
  • This supernatant is then transferred into another tube and the IgGs and IgMs are assayed by means of a sandwich format using solid phases and conjugates consisting of anti-human IgM and anti-human IgG antibodies.
  • This technique is laborious since it requires pretreatment of the sample so as to conserve only the antigen-specific Igs.
  • the subject of the present invention is thus a method for the in vitro diagnostic detection of an infection with a microorganism, comprising the simultaneous detection of the immunoglobulins G or of the total immunoglobulins and of the immunoglobulins M directed against said microorganism, present in a biological sample, which method comprises the following steps:
  • the groups of said particles differ from one another by virtue of fluorochromes, detectable by a suitable detector.
  • the suitable detector is associated with a flow cytometer.
  • the labelling of the detection antigen may be direct or indirect.
  • the detection antigen may carry a biotin, which is revealed by the addition of labelled avidin or streptavidin.
  • the microorganism is a human virus, in particular the human hepatitis virus.
  • a subject of the invention is also a diagnostic kit or a set of reagents for carrying out the detection method, comprising in particular particles, each carrying at least one specific detectable physical parameter, and belonging to at least two different groups, one of the groups carrying an anti-IgM capture antibody and the other group carrying a capture antigen derived from a microorganism to be detected.
  • the inventors have first of all carried out a multiplex assay for simultaneous detection, in a single receptacle, of anti-HAV IgG and IgM in a sample (serum or plasma), combining two formats by immunocapture (see the details of the protocol and results in the Experimental section, comparative Example 1, and the assay formats in FIG. 1 ):
  • the HAV antigen was added. After a second incubation, the HAV antigen (Ag HAV) was bound to the two types of complexes formed.
  • the IgM detection reached an acceptable sensitivity, even at low concentrations, which represent quite a common situation following an HAV infection.
  • the sensitivity of the IgG detection was, on the other hand, clearly insufficient, in this configuration, due to the large natural abundance of IgGs (all antigenic specificities included) in the sample.
  • the anti-IgG superparamagnetic particles were very rapidly saturated with the IgGs not specific for HAV, present in the sample, and no longer captured enough anti-HAV IgG, especially at low concentrations of anti-HAV IgG. This resulted in an insufficient analytical sensitivity.
  • the inventors therefore designed other assay formats in order to solve the problem of the lack of “IgG sensitivity” described in the above assay.
  • the inventors showed that the multiplex combining the two formats described hereinafter for Example 2 (see the details of the protocol and the results in the Experimental section, Example 2, and the assay formats in FIG. 2 ) is able to simultaneously detect, in a single receptacle, the low IgG concentrations without desensitizing the IgM detection, and, furthermore, makes it possible to differentiate, in a completely sensitive and specific manner, between the anti-HAV IgM antibodies and the total anti-HAV immunoglobulins.
  • this method for simultaneously detecting, in a single receptacle, anti-HAV IgG and IgM in a sample (serum or plasma) [which method is therefore the method according to the present invention] combines two assay formats (an “immunoglobulin capture” assay format according to Duermeyer W. et al., for the IgMs and a “double antigen sandwich” assay format according to Maiolini R., et al., for the IgGs):
  • a biotinylated HAV antigen is added. After a second incubation, the HAV antigen is bound to the two types of complexes formed.
  • the invention which results in sensitive and differential detection of anti-HAV IgMs and total Igs, is entirely surprising: this is because there was a high risk, with the combination, in a single receptacle, of the two formats according to the method of the invention, that there would be competition for the anti-HAV IgMs of the sample, between the immobilized HAV antigen and the immobilized anti-IgM antibody.
  • the simultaneous implementation of the two formats described above in one and the same receptacle, there was a risk that some of the anti-HAV IgMs of the sample would be captured (as represented by the dashed arrow in FIG.
  • the inventors have similarly used the multiplex method according to the invention for simultaneously detecting IgG and IgM antibodies directed against the hepatitis B virus capsid (detection of HB core IgG and IgM antibodies). To this effect, see the Experimental section, Example 3, and the assay formats in FIG. 3 .
  • the inventors propose a method for the general detection of IgGs and IgMs, in a multiplex format, that can be adapted to many microorganisms for which it is important, from a diagnostic point of view, to detect IgGs and IgMs.
  • a “biological sample” preferably consists of a biological fluid, such as blood, plasma, serum, urine, cerebrospinal fluid, saliva, etc.
  • the sample is plasma or serum.
  • the test sample is preferably of human origin, but may also originate from an animal for which detection of a microbiological infection is necessary.
  • multiplex detection refers, in the context of the present invention, to the simultaneous detection of at least two types of antibodies directed against the same or several infectious microorganism(s), and chosen from the group consisting of immunoglobulins M, G, A, D and E and total immunoglobulins in the blood.
  • antibody refers to any whole antibody or functional fragment of an antibody comprising or consisting of at least one antigenic combination site allowing said antibody to bind to at least one antigenic determinant of an antigenic compound.
  • antibody fragments mention may be made of Fab, Fab′ and F(ab′) 2 fragments and also scFv chains (Single chain variable fragment), dsFv chains (Double-stranded variable fragment), etc. These functional fragments may in particular be obtained by genetic engineering.
  • antigenic fragment or “antigen” is intended to mean all or part of a natural or recombined protein of an infectious microorganism such as the hepatitis A virus, capable of inducing antibody synthesis in an infected patient or in an immunized animal.
  • the expression “antigen derived from the microorganism”, whether it is for capture or detection, is intended to mean any antigen selected from the group consisting of a lysate of said microorganism, one of its natural antigens that has been semi-purified or purified, a recombined protein, a fragment thereof and a synthetic peptide.
  • capture antigen is intended to mean an antigenic fragment attached to a solid phase, which is capable of being recognized by antibodies directed against the microorganism, such as anti-HAV antibodies, and of allowing affinity binding with the latter.
  • capture antibody is intended to mean an antibody or a part of an antibody, attached to a solid phase, which is capable of retaining at least one antigenic determinant of an antigenic compound present in a biological sample, by affinity binding.
  • the anti-IgM capture antibodies and the capture antigens may be attached to the particles by any suitable technique. They may be attached by direct covalence, or noncovalently, in particular by affinity. The direct covalent attachment may be carried out by means of activation of the carboxylic groups present on the particles, involving bonding via hydroxysuccinimide or carbodiimide for example.
  • detection antigen is intended to mean a labelled antigen which makes it possible either to detect IgM antibodies by the immunocapture method, or to detect IgG antibodies by the conventional antigen-antibody-antigen sandwich method, also called “double antigen sandwich” method (Maiolini et al. (1978)).
  • the detection antigen may be identical to or different from the capture antigen.
  • labelled refers both to direct labelling (by means of fluorochromes, luminescent compounds, etc.) and to indirect labelling (for example, by means of antibodies or antigens, themselves directly labelled, or using reagents of a labelled “affinity pair”, such as, but not exclusively, the labelled avidin-biotin pair, etc.).
  • the monoclonal antibodies may be obtained according to the conventional method of lymphocyte fusion and hybridoma culture described by Köhler and Milstein ( Nature, 256, p. 495-497 (1975)). Other methods for preparing monoclonal antibodies are also known (Harlow et al. editors, Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory (1988)).
  • the monoclonal antibodies may be prepared by immunizing a mammal (for example, a mouse, a rat, a rabbit, or even a human being, etc.) and by using the lymphocyte fusion technique which produces hybridomas (Köhler and Milstein, 1975, above).
  • monoclonal antibodies can be produced by expression of a nucleic acid cloned from a hybridoma.
  • Antibodies can also be produced by the phage display technique, by introducing antibody cDNAs into vectors, which are typically filamentous phages (for example, Fuse5 for E. coli , Scott et al. ( Science, 249, pp. 386-390 (1990)). The latter constitute libraries and exhibit scFv fragments at their surface. Protocols for constructing these antibody libraries are described in Marks et al. (1991) ( J. Mol. Biol., 222, pp. 581-597, (1991)).
  • polyclonal antibodies can be obtained from the serum of an animal immunized against an antigen of peptide nature, according to the usual protocols.
  • a polypeptide in particular a recombined polypeptide, or an oligopeptide, can be used for example as immunogen.
  • rabbits are immunized with the equivalent of 1 mg of the peptide immunogen according to the procedure described by Benoit et al. [ PNAS USA, 79, pp. 917-921 (1982)].
  • the animals are given injections of 200 ⁇ g of antigen, at four-week intervals, and are bled 10 to 14 days later. After the third injection, the ability of the antiserum to bind to the iodine-radiolabelled antigenic peptide, prepared by the chloramine-T method, is evaluated. It is then purified by chromatography on an ion exchange column consisting of carboxymethylcellulose (CMC). The antibody molecules collected by elution are then adjusted to the desired concentration by methods well known to those skilled in the art, for example using DEAE Sephadex in order to obtain the IgG fraction.
  • CMC carboxymethylcellulose
  • particles is intended to mean any particles, preferably approximately spherical in shape (they are then generally called beads), having sizes that may be between 0.3 ⁇ m and 100 ⁇ m in diameter, and preferably between 0.5 ⁇ m and 40 ⁇ m. Such particles are manufactured, for example, by the companies Luminex, Merck or Dynal.
  • the particles preferably consist of polymers which are inert with respect to the constituents of the biological samples; they are solid and insoluble in the samples.
  • the polymers used may be polyesters, polyethers, polyolefins, polyamides, polysaccharides, polyurethanes or celluloses. Binders may also be used in order to give integrity and structure to the particles.
  • Functional groups may be incorporated with these polymers in order to allow the attachment or coupling of macromolecules of biological interest (proteins, lipids, carbohydrates, nucleic acids).
  • These functional groups known to those skilled in the art, may be amine functions (—NH 2 ) or ammonium functions (—NH 3+ or —NR 3+ ), alcoholic functions (—OH), carboxylic functions (—COOH) or isocyanate functions (—NCO).
  • the monomers most commonly used for introducing COOH functions into polyolefins are acrylic acid or methacrylic acid.
  • the attachment of reagents to the surface of the particles can be carried out by electrostatic attractions, affinity interactions, hydrophobic interactions or covalent coupling. Covalent coupling is preferred.
  • the particles used here can be distinguished in that they carry specific detectable physical parameters, i.e. differential markers for distinguishing them from one another by flow cytometry.
  • the particles may be impregnated with one or more dyes (for example fluorescent, luminescent, etc.), where appropriate at various concentrations, or with a label of radioisotope, enzymatic, etc., type (Venkatasubbarao S. “Microarrays-Status and prospects” Trends in Biotechnology December 2004, 22(12):630-637; Morgan et al, “Cytometric bead array: a multiplexed assay platform with applications in various areas of biology”, Clin. Immunol. (2004) 100:252-266).
  • particles of various sizes may be used.
  • the distinguishable particles emit luminescent or fluorescent signals.
  • Superparamagnetic fluorescent beads from Luminex may, for example, be used.
  • physicochemical properties may also make it possible, during the reaction with the biological sample, to separate the fractions captured by these microparticles from those which are not bound. This separation may be carried out, inter alia, by centrifugation, filtration or magnetization. Separation by magnetization is preferred, and for this, beads containing paramagnetic, ferromagnetic, ferrimagnetic and metamagnetic components may be used. Paramagnetic components are preferred, for instance iron, cobalt, nickel or metal oxides such as Mn 2 O 3 , Cr 2 O or Fe 3 O 4 . The amount of magnetic components may be between 2% and 50% (by weight), and preferably between 3% and 25%.
  • the present invention uses an immunoassay method which combines flow cytometry with the use of a particulate, preferably superparamagnetic, support as solid phase (using, in one and the same receptacle, several categories or groups of distinct particles).
  • the final detection phase according to the method of the invention generally comprises:
  • the particles are preferably subjected to a measurement by flow cytometry, as described, for example, in Luminex patent application WO97/14028.
  • a reagent antibody or antigen
  • the particles thus exposed to the sample then pass into an examination zone (i.e. a cytometer), where the data relating to the classification parameters (for example, the fluorescence emission intensities), and preferably also the data relating to the presence or absence of a complex formed between the reagent and the analyte of interest, are collected.
  • the particles emit fluorescent signals
  • the fluorescence signal emitted by the immunocomplexes formed on each particle is measured using a particulate flow cytometer with a laser reader (for example, of the LuminexTM apparatus type).
  • the present invention thus makes it possible to obtain, by means of a simple and automatable protocol, two separate and sensitive measurements, one for the IgMs, the other for the total immunoglobulins, directed against the same infectious microorganism.
  • the present invention is described below, more particularly with a view to the simultaneous detection of IgMs and IgGs (or total Igs) for the hepatitis A virus and for the hepatitis B virus, and for the simultaneous detection of IgMs and IgGs (or total Igs) for Treponema pallidum , the infectious bacterial agent responsible for syphilis.
  • the present invention applies broadly to all viruses (HSV, Dengue virus, other flaviviruses, such as the West Nile virus; the rubella and influenza viruses, VZV, CMV, etc.), to all bacteria ( Treponema pallidum, Borrelia burgdorferi , etc.) and/or to all parasites ( Toxoplasma gondii , etc.) in which there similarly exists a need to simultaneously detect IgMs and IgGs (or total immunoglobulins), in the same assay receptacle, without any loss of sensitivity.
  • viruses HSV, Dengue virus, other flaviviruses, such as the West Nile virus; the rubella and influenza viruses, VZV, CMV, etc.
  • IgMs and IgGs or total immunoglobulins
  • the sample does not need to undergo a pretreatment such as an enzymatic reaction, digestion or modification, or such as a chemical reaction or modification, or the like, etc. (for example, by zonal or sucrose-gradient ultracentifugation, gel filtration, IgG adsorption via staphylococcal protein A or via an anti-gamma Fc antibody or else cleavage of the IgMs with ⁇ -mercaptoethanol.
  • a pretreatment such as an enzymatic reaction, digestion or modification, or such as a chemical reaction or modification, or the like, etc.
  • the receptacle may be any solid container, for example a test tube, a microplate well or a reaction cuvette made of polypropylene.
  • the elimination of the unbound reagents may be carried out by any technique known to those skilled in the art, such as washing by means of repeated centrifugation steps or taking advantage of the superparamagnetic nature of the beads, by using magnets.
  • the microorganism is chosen from the group consisting of human viruses, bacteria and parasites, preferably single-cell parasites.
  • the microorganism is chosen from the group consisting of human viruses.
  • the microorganism is chosen from the group consisting of human hepatitis viruses such as the HAV and HBV viruses.
  • said microorganism is the human hepatitis A virus (HAV), for which it is then possible to obtain a lower detection limit for total anti-HAV immunoglobulins of approximately 20 mIU/ml.
  • HAV human hepatitis A virus
  • a subject of the present invention is also a set of reagents for carrying out the method according to the invention.
  • a subject of the present invention is also a kit of reagents for carrying out the method according to the invention.
  • the type of simultaneous and combined detection of IgMs directed against an infectious microorganism and of IgG antibodies or total Igs against this same infectious microorganism is, in the context of the present invention, called a “multiplex detection” as opposed to a “simplex detection” (where the IgM and IgG or total Ig detections are carried out independently, i.e. are not combined).
  • the present invention is also directed towards and encompasses all the variants of a simultaneous detection method, which variants may be obtained by methods that are known per se or can be deduced by those skilled in the art without departing from the spirit of the present invention.
  • FIG. 1 is a scheme showing the detection of anti-HAV IgGs and IgMs by double immunocapture format (prior art).
  • FIG. 2 is a scheme showing the method of the invention for detecting total anti-HAV Igs in sandwich format and anti-HAV IgMs by immunocapture.
  • FIG. 3 is a scheme showing the method of the invention for detecting total anti-HBc Igs in sandwich format and anti-HBc IgMs by immunocapture.
  • FIG. 4 is a graph showing a comparison of the standard ranges for total anti-HAV Igs assayed by IgG unit format (immunocapture) and by total Ig unit sandwich format.
  • FIG. 5 is a graph showing a comparison of the standard ranges for total anti-HAV Igs assayed by unit sandwich format and by multiplex.
  • FIG. 6 is a scheme showing the method of the invention for detecting total anti- Treponema pallidum Igs in sandwich format and anti- Treponema pallidum IgMs by immunocapture
  • FIG. 1 The principle of this assay according to the prior art is illustrated in FIG. 1 .
  • the BioPlex 2200® analyzer (Bio-Rad, Marnes la Coquette, France) was used according to the manufacturer's instructions.
  • This automated immunoanalytical device contains a flow cytometer and a Luminex 100TM detector (Luminex Corp., Austin, Tex., United States) and uses heterogeneous sets of superparamagnetic particles.
  • Each group of particles composed of polystyrene and methacrylic acid (COON function), and having a size of 8 ⁇ m in diameter, is manufactured with various percentages of fluorochromes (CL1 and CL2) producing a unique identification code assigned to each group of particles and detectable by the laser of the Luminex 100TM detector (Luminex Corp., Austin, Tex., United States).
  • the beads pass one by one through a flow cell, at the centre of a liquid matrix, so as to be simultaneously excited and read by two separate lasers. The measurements are carried out as each bead passes through.
  • the 638 nm red laser excites the identifying fluorochromes (CL1 and CL2) embedded at the surface of each particle and the composite signal is interpreted so as to identify the analyte of the particle. By identifying the category of particle, this laser therefore serves to identify the ongoing assay.
  • the 532 nm green laser excites the fluorescent probe (conjugate labelled with phycoerythrin (PE)) and the fluorescence emitted is proportional to the conjugate attached to the particle. This laser therefore serves to measure the reactivity of the analyte immobilized on said particle.
  • the system software converts the signal of the conjugate into a relative fluorescence intensity (RFI) value.
  • the signals are then compared to a standard curve specific to the assay in order to determine the concentration of the analyte.
  • a ratio may also be calculated in order to classify the result qualitatively as positive or negative.
  • LuminexTM superparamagnetic particles Two distinct groups of LuminexTM superparamagnetic particles (Luminex Corp., Austin, Tex., United States) were used.
  • Each group of particles is coated with a ligand specific to a particular assay.
  • Each ligand is coupled using a heterobifunctional reagent.
  • HAV antigen from Viral Antigen, Memphis, Tenn., United States.
  • Anti-HAV mouse monoclonal antibody (Bio-Rad, Marnes la Coquette, France) coupled to phycoerythrin (PE) using a heterobifunctional reagent, known per se to those skilled in the art.
  • the immunoreactions were carried out in a polypropylene reaction cuvette with a volume of 1 ml.
  • the WHO total anti-HAV immunoglobulin standard (code 97/646) was reconstituted according to the recommendations and diluted so as to give the following standard points: 0; 20; 80; 160; 320 and 640 mIU/ml.
  • washing steps are then carried out: separation of the solid and liquid phases by magnetization and three successive washes with at least 300 ⁇ l of washing solution. At the final wash, the particles are resuspended.
  • HAV antigen (Ag HAV) solution 50 ⁇ l of HAV antigen (Ag HAV) solution are distributed into each reaction cuvette.
  • conjugate anti-HAV antibody-phycoerythrin, i.e. Mab-PE
  • the particles of each well are resuspended by adding to them 35 ⁇ l of washing solution with agitation.
  • the particle suspension of each cuvette is read using the two laser rays.
  • a ratio is calculated relative to a cut-off value.
  • the cut-off value corresponds to the RFI value of the standard point at 20 mIU/ml considered to be the protection cut-off.
  • Sample ⁇ ⁇ ⁇ ratio mean * ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ ⁇ R ⁇ ⁇ F ⁇ ⁇ I ⁇ ⁇ signal ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ sample Cut ⁇ - ⁇ off ⁇ ⁇ value
  • the anti-HAV IgG immunocapture format in order to achieve an analytical sensitivity of 20 mIU/ml.
  • the multiplex detection method according to the invention is described below and in FIG. 2 .
  • LuminexTM superparamagnetic particles Two distinct groups of LuminexTM superparamagnetic particles (Luminex Corp., Austin, Tex., United States) are used:
  • HAV antigen (Viral Ag, Memphis, Tenn., USA) labelled with biotin (Pierce, Rockford, Ill., United States).
  • Streptavidin (abbreviated to “Strepta”, Roche Mannheim, Germany), coupled to phycoerythrin (abbreviated to “PE”) from Cyanotech, Hi., United States.
  • PE phycoerythrin
  • the diluents for the beads and for conjugates 1 and 2 are identical to those of example 1.
  • the WHO total anti-HAV immunoglobulin standard (code 97/646) is identical to that used in example 1.
  • the human samples assayed are plasma or serum samples which are positive or negative for anti-HAV total immunoglobulins and/or IgMs. These samples originate from internal sample libraries, made up of specimen bags and from samples sold by the following companies:
  • the human samples assayed can be divided up into:
  • the multiplex protocol i.e. the total Ig protocol+the IgM protocol
  • two unit protocols a total Ig protocol and an IgM protocol
  • These three protocols are identical except for the step of adding the immunoreactive superparamagnetic particles which are used.
  • the multiplex protocol uses the two groups of beads and each unit protocol uses a single group of beads.
  • the amount of particles of group 1 (carrying anti-IgM antibodies) used in the IgM unit protocol and the multiplex protocol remains the same.
  • the amount of particles of group 2 (carrying HAV antigen) used in the total Ig unit protocol and the multiplex protocol remains the same.
  • conjugate 1 biotinylated HAV antigen, i.e. “Ag HAV biotin”
  • conjugate 2 streptavidin-phycoeryhtrin, i.e. “Strepta-PE”
  • each reaction cuvette is resuspended by adding to them 35 ⁇ l of washing solution with agitation.
  • the particle suspension of each cuvette is read using the two laser rays.
  • a ratio is calculated relative to a cut-off value.
  • the cut-off value corresponds to the RFI value of the standard point of 20 mIU/ml considered to be the protection cut-off.
  • Sample ⁇ ⁇ ⁇ ratio mean * ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ ⁇ R ⁇ ⁇ F ⁇ ⁇ I ⁇ ⁇ signal ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ sample Cut ⁇ - ⁇ off ⁇ ⁇ value
  • the cut-off value is the mean of the RFIs of the negative samples+12 standard deviations.
  • the sample ratio calculated is thus the following:
  • Sample ⁇ ⁇ ⁇ ratio mean * ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ ⁇ R ⁇ ⁇ F ⁇ ⁇ I ⁇ ⁇ signal ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ sample cut ⁇ - ⁇ off ⁇ ⁇ value
  • the multiplex detection method according to the invention was also used for assaying anti-HBc total Igs and IgMs. This method is illustrated in FIG. 3 and described below.
  • the material used is equivalent to that of example 2, with the exception of the particles, of biotinylated conjugate 1 and of the samples tested.
  • LuminexTM superparamagnetic particles Two distinct groups of LuminexTM superparamagnetic particles (Luminex Corp., Austin, Tex., United States) are used.
  • the human samples assayed are plasma or serum samples that are positive or negative for total anti-HBc immunoglobulins and/or anti-HBc IgM. These samples come from internal sample libraries, from samples sold by the companies:
  • the human samples assayed can be divided up into:
  • the protocols used are identical to protocols A, B and C described above in example 2, with the exception of the sample volume used in step 1, which is 5 ⁇ l+250 ⁇ l of diluent for step 1.
  • the cut-off value is the mean of the RFIs of the negative samples+12 standard deviations.
  • the sample ratio calculated relative to the cut-off value is thus the following:
  • Sample ⁇ ⁇ ⁇ ratio mean * ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ ⁇ R ⁇ ⁇ F ⁇ ⁇ I ⁇ ⁇ signal ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ sample cut ⁇ - ⁇ off ⁇ ⁇ value
  • the multiplex detection method according to the invention was also used for assaying total anti- Treponema pallidum Igs and anti- Treponema pallidum IgMs, Treponema pallidum being an infectious bacterial agent responsible for syphilis. This method is illustrated in FIG. 6 and described below.
  • the material used is equivalent to that of examples 2 and 3, with the exception of the particles, of biotinylated conjugate 1 and of the samples tested.
  • LuminexTM superparamagnetic particles Two distinct groups of LuminexTM superparamagnetic particles (Luminex Corp., Austin, Tex., United States) are used.
  • the human samples assayed are plasma or serum samples that are positive or negative for total anti- Treponema pallidum immunoglobulins and/or anti- Treponema pallidum IgM.
  • the human samples assayed can be divided up into:
  • the protocols used are identical to protocols A, B and C described above in example 2, with the exception of the volumes in step 1, which are 100 ⁇ l for the sample and 100 ⁇ l for the beads, and in step 2, which is 100 ⁇ l of solution of conjugate 1 (biotinylated Treponema pallidum antigens).
  • the cut-off value is the mean of the RFIs of the negative samples divided by 0.3.
  • the sample ratio calculated relative to the cut-off value is thus the following:
  • Sample ⁇ ⁇ ⁇ ratio mean * ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ ⁇ R ⁇ ⁇ F ⁇ ⁇ I ⁇ ⁇ signal ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ sample cut ⁇ - ⁇ off ⁇ ⁇ value
  • the method of the invention can be readily automated through the use of an automated device, such as, for example, BioPlex 2200 from Bio-Rad, which enables the assay protocols to be carried out simultaneously and rapidly, in a single receptacle, and the signals to be read in a single step.
  • an automated device such as, for example, BioPlex 2200 from Bio-Rad, which enables the assay protocols to be carried out simultaneously and rapidly, in a single receptacle, and the signals to be read in a single step.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US12/600,297 2007-06-08 2008-06-06 Multiplex Method for Detecting an Infection Abandoned US20100151445A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/600,297 US20100151445A1 (en) 2007-06-08 2008-06-06 Multiplex Method for Detecting an Infection

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0755626A FR2917173B1 (fr) 2007-06-08 2007-06-08 Procede multiplexe de detection d'une infection
FR0755626 2007-06-08
US92906107P 2007-06-11 2007-06-11
PCT/EP2008/057111 WO2008148883A1 (en) 2007-06-08 2008-06-06 Multiplex method for detecting an infection
US12/600,297 US20100151445A1 (en) 2007-06-08 2008-06-06 Multiplex Method for Detecting an Infection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/057111 A-371-Of-International WO2008148883A1 (en) 2007-06-08 2008-06-06 Multiplex method for detecting an infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/892,521 Continuation US9523685B2 (en) 2007-06-08 2013-05-13 Multiplex method for detecting an infection

Publications (1)

Publication Number Publication Date
US20100151445A1 true US20100151445A1 (en) 2010-06-17

Family

ID=38457970

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/600,297 Abandoned US20100151445A1 (en) 2007-06-08 2008-06-06 Multiplex Method for Detecting an Infection
US13/892,521 Active 2029-02-01 US9523685B2 (en) 2007-06-08 2013-05-13 Multiplex method for detecting an infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/892,521 Active 2029-02-01 US9523685B2 (en) 2007-06-08 2013-05-13 Multiplex method for detecting an infection

Country Status (9)

Country Link
US (2) US20100151445A1 (pt)
EP (1) EP2160605B1 (pt)
JP (1) JP5216852B2 (pt)
CN (1) CN101711361B (pt)
BR (1) BRPI0812771B8 (pt)
CA (1) CA2687827C (pt)
EA (1) EA017206B1 (pt)
FR (1) FR2917173B1 (pt)
WO (1) WO2008148883A1 (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014176535A1 (en) * 2013-04-26 2014-10-30 Bio-Rad Laboratories, Inc. Multiplex hepatitis b assay
WO2016144962A1 (en) * 2015-03-10 2016-09-15 Bio-Rad Laboratories, Inc. Combination treponemal and non-treponemal syphilis test
US9689044B2 (en) 2011-01-26 2017-06-27 The Brigham And Women's Hospital, Inc. Assays and methods to sequence microbes directly from immune complexes

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118775A1 (en) * 2013-01-29 2014-08-07 Bio-Rad Haifa Ltd Detection assays employing magnetic nanoparticles
CN104714028B (zh) * 2015-03-02 2017-01-25 深圳市凯瑞德生物技术有限公司 一种检测IgM抗体的免疫检测方法
US11209431B2 (en) 2015-10-06 2021-12-28 Bio-Rad Laboratories, Inc. Borrelia immunoassays and materials therefor
CN108351351B (zh) 2015-11-09 2021-10-29 生物辐射实验室股份有限公司 使用亲和素和生物素的试验
EP3508849B1 (en) * 2016-08-31 2023-04-19 Eiken Kagaku Kabushiki Kaisha Antibody measurement method using antigen-carrying insoluble carrier particles on which antigen is immobilized by different methods, and reagent for antibody measurement
ES2929392T3 (es) * 2017-03-01 2022-11-28 Hoffmann La Roche Sistemas, procedimiento y medio legible por ordenador para clasificar una muestra biológica con respecto a la presencia de un analito
WO2020023901A1 (en) * 2018-07-27 2020-01-30 Veravas, Inc. Method for detecting biomarkers
WO2021030935A1 (zh) * 2019-08-16 2021-02-25 深圳迈瑞生物医疗电子股份有限公司 全新型总抗体测定的免疫分析模式
WO2021203044A2 (en) * 2020-04-03 2021-10-07 Icahn School Of Medicine At Mount Sinai High-throughput assay for circulating antibodies against severe acute respiratory syndrome coronavirus 2
CN115397465A (zh) * 2020-04-24 2022-11-25 美国西门子医学诊断股份有限公司 用于针对抗体的免疫测定的校准和质量控制试剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829012A (en) * 1985-01-24 1989-05-09 L'association Internationale Abut Scientifique, Dite: "Institut International De Pathologie Cellulaire Et Moleculaire" Method for immunological assay of antibodies of various types in a liquid sample

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1172561A (en) 1981-01-28 1984-08-14 Richard H. Decker Igm detection method
JPS6270764A (ja) * 1985-03-08 1987-04-01 Sanko Junyaku Kk 血清中の免疫抗体測定方法
EP0304238A3 (en) * 1987-08-14 1991-10-09 Ortho Diagnostic Systems Inc. Method for detecting and confirming the presence of antibodies
JPH05133952A (ja) * 1991-04-03 1993-05-28 Syntex Usa Inc イムノグロブリン類のイムノアツセイ
EP0507587A3 (en) * 1991-04-03 1993-03-03 Syntex (U.S.A.) Inc. Immunoassay for immunoglubulins
WO1999026067A1 (en) * 1997-11-18 1999-05-27 Bio-Rad Laboratories, Inc. Multiplex flow immunoassays with magnetic particles as solid phase
ITTO980473A1 (it) * 1998-06-02 1999-12-02 Sorin Diagnostics S R L Nuovo procedimento per la rivelazione di anticorpi e/o isotipi di anticorpi specifici per almeno due differenti fasi di un'infezione
AU2001249444A1 (en) * 2000-03-28 2001-10-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the simultaneous detection of multiple analytes
JP2002310875A (ja) * 2001-04-16 2002-10-23 National Institute Of Advanced Industrial & Technology 梅毒検査試薬及び梅毒検査方法
WO2003093511A1 (en) * 2002-04-30 2003-11-13 Merck & Co., Inc. Human papillomavirus multiplexed assay
FR2839555B1 (fr) * 2002-05-10 2007-07-27 Bio Rad Pasteur Procede de detection simultanee d'un antigene et d'un anticorps d'un microorganisme infectieux
CN1164948C (zh) * 2002-06-06 2004-09-01 成都夸常科技有限公司 一种基于抗原抗体反应的试剂盒
CN1902496A (zh) * 2003-11-07 2007-01-24 赫普金尼克斯股份有限公司 结合测定组分

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829012A (en) * 1985-01-24 1989-05-09 L'association Internationale Abut Scientifique, Dite: "Institut International De Pathologie Cellulaire Et Moleculaire" Method for immunological assay of antibodies of various types in a liquid sample

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Crandall, et al. The Relative Proportions of IgG-, IgA- and IgM-containing Cells in Rabbit Tissues during Experimental Trichinosis. Immunology. 1967; 12: 147-158 *
Kuller, et al. Development of a whole-virus multiplex flow cytometric assay for antibody screening of a specific pathogen-free primate colony. Diagnostic microbiology and infectious disease. 2005; 53(3): 185-93 *
Kuller, et al. Development of a whole-virus multiplex flow cytometric assay for antibody screening of a specific pathogen-free primate colony. Diagnostic microbiology and infectious disease. 2005; 53(3): 185-93. *
Louis, et al. A new and simple non-magnetic technique to highly and rapidly enrich hematopoietic progenitors from mouse bone marrow. Blood 98 (11 Part 2): p118b November 16, 2001. *
Monceyron and Grinde Detection of Hepatitis-A Virus in Clinical and Environmental Samples by Immunomagnetic Separation and PCR. Journal of Virological Methods. 1994; 46(2): 157-166. *
Schønau, et al. A one-step solid phase immunoassay for simultaneous detection of serum IgG and IgM antibodies to Borrelia burgdorferi. Journal of Immunological Methods. 1998; 218: 9-17 *
Schønau, et al. A one-step solid phase immunoassay for simultaneous detection of serum IgG and IgM antibodies to Borrelia burgdorferi. Journal of Immunological Methods. 1998; 218: 9-17. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9689044B2 (en) 2011-01-26 2017-06-27 The Brigham And Women's Hospital, Inc. Assays and methods to sequence microbes directly from immune complexes
WO2014176535A1 (en) * 2013-04-26 2014-10-30 Bio-Rad Laboratories, Inc. Multiplex hepatitis b assay
US9927439B2 (en) 2013-04-26 2018-03-27 Bio-Rad Laboratories, Inc. Multiplex hepatitis B assay
CN109828110A (zh) * 2013-04-26 2019-05-31 生物辐射实验室股份有限公司 多重乙肝试验
WO2016144962A1 (en) * 2015-03-10 2016-09-15 Bio-Rad Laboratories, Inc. Combination treponemal and non-treponemal syphilis test
US10324091B2 (en) 2015-03-10 2019-06-18 Bio-Rad Laboratories, Inc. Combination treponemal and non-treponemal syphilis test
US10648981B2 (en) 2015-03-10 2020-05-12 Bio-Rad Laboratories, Inc. Combination treponemal and non-treponemal syphilis test
US10942182B2 (en) 2015-03-10 2021-03-09 Bio-Rad Laboratories, Inc. Combination treponemal and non-treponemal syphilis test
US11913954B2 (en) 2015-03-10 2024-02-27 Bio-Rad Laboratories, Inc. Combination treponemal and non-treponemal syphilis test

Also Published As

Publication number Publication date
EA200971123A1 (ru) 2010-06-30
US20130273525A1 (en) 2013-10-17
BRPI0812771B1 (pt) 2019-01-22
CN101711361A (zh) 2010-05-19
CA2687827C (en) 2017-08-29
EP2160605B1 (en) 2017-11-01
JP5216852B2 (ja) 2013-06-19
WO2008148883A1 (en) 2008-12-11
CA2687827A1 (en) 2008-12-11
EA017206B1 (ru) 2012-10-30
JP2010529443A (ja) 2010-08-26
CN101711361B (zh) 2016-08-31
FR2917173A1 (fr) 2008-12-12
US9523685B2 (en) 2016-12-20
BRPI0812771A2 (pt) 2014-12-02
EP2160605A1 (en) 2010-03-10
FR2917173B1 (fr) 2009-07-31
BRPI0812771B8 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
US9523685B2 (en) Multiplex method for detecting an infection
US10732111B2 (en) Automated immunoanalyzer system for performing diagnostic assays for allergies and autoimmune diseases
US8580531B2 (en) Detection of antigens carried by erythrocytes and of anti-erythrocyte antibodies
EP0296398B1 (en) Immunoassay method for detecting antibodies to antigens
US6087188A (en) Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand
JP2636331B2 (ja) 抗原特異的な抗体の一段階測定法およびそれに適する試薬
KR20180063313A (ko) 면역검정에서의 간섭 감소를 위한 방법
US20230072761A1 (en) Immunoassay for Detecting Zika Virus Infection
JPH09504094A (ja) 磁性ラテックス粒子および非磁性粒子を用いて免疫物質をアッセイする方法
AU2015239040B2 (en) Control means for implementing multiplex analysis methods
EP0201211A1 (en) Method and compositions for visual solid phase immunoassays based on luminescent microspheric particles
US20080206790A1 (en) Assay for determining the presence or amount of newly synthesized antibodies
EP4191244A1 (en) Test reagent with ameliorated signal reduction
CZ289582B6 (cs) Způsob pro detekování aktivní produkce protilátek
EP0304238A2 (en) Method for detecting and confirming the presence of antibodies
Lim et al. A two-particle turbidometric latex immunoassay for the detection of specific IgM antibodies
JP2021099243A (ja) 免疫学的測定法
JPH02287258A (ja) 体液中の感染症原因生物に対する抗体の測定方法およびそのための剤
Ansarl et al. Diagnosis of viruses by immunoassays
MXPA99011805A (en) Methods for assaying antibody and device for assaying antibody

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIO-RAD INNOVATIONS, FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:BIO-RAD PASTEUR;REEL/FRAME:028344/0008

Effective date: 20110609

Owner name: BIO-RAD PASTEUR, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHARPENTIER, CHRISTINE;GADELLE, STEPHANE;LAMBERT, NADINE;AND OTHERS;REEL/FRAME:028341/0148

Effective date: 20120314

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BIO-RAD EUROPE GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIO-RAD INNOVATIONS;REEL/FRAME:049122/0754

Effective date: 20180306